News: Specialized Press
The Methylphenidate OROS shown to be effective in the treatment of adults with hyperactivity
Source: Journal of Clinical Psychopharmacology. 2009 JUN 29 (3) :239-247 / Date: June 2009 / Category: Specialized Press
The objective is evaluating the efficacy and safety of methylphenidate OROS (Concerta, McNeil Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) to treat attention disorders (ADHD) in adults. A group of scientists led by A. Adler has conducted a study that appears in the Journal of Clinical Psychopharmacology.
During 7 weeks methylphenidate OROS was administered at doses of 36, 54, 72, 90 or 108 mg / day in adults with ADHD. Two hundred Twenty-six subjects were included (110 subjects received methylphenidate OROS, 116 placebo subjects).
The researchers found that methylphenidate OROS led to an increase in the improvement of the symptoms of ADHD as opposed to placebo. In addition, the methylphenidate OROS was well tolerated.
The study concluded that in a dose escalation from 36 to 108 mg / day, methylphenidate OROS is effective and well tolerated in the treatment of ADHD in adults.